Ana Espinel-Ingroff
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ana Espinel-Ingroff has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
A. Fothergill
VCU Medical Center, Richmond, Virginia,1 University of Texas Health Science Center, San Antonio, Texas,2 Case Western Reserve University, Cleveland, Ohio,3 Wayne State University, Detroit, Michigan,4 University of Texas-Houston Medical School, Houston, Texas,5 University of Iowa College of Medicine, Iowa City, Iowa,6 Duke University, Durham, North Carolina,7 National Cancer Institute, Bethesda, Maryland8
4 shared publicationsM. Rinaldi
VCU Medical Center, Richmond, Virginia,1 University of Texas Health Science Center, San Antonio, Texas,2 Case Western Reserve University, Cleveland, Ohio,3 Wayne State University, Detroit, Michigan,4 University of Texas-Houston Medical School, Houston, Texas,5 University of Iowa College of Medicine, Iowa City, Iowa,6 Duke University, Durham, North Carolina,7 National Cancer Institute, Bethesda, Maryland8
4 shared publicationsM. A. Pfaller
VCU Medical Center, Richmond, Virginia,1 Public Health, Ancona, Italy,2 Instituto Salud Carlos III, Majadahonda, Spain,3 University of Texas Health Science Center, San Antonio, Texas,4 University of Iowa College of Medicine, Iowa City, Iowa,5 Medical Center Nijmegen, Nijmegen, The Netherlands6
3 shared publicationsF. Barchiesi
VCU Medical Center, Richmond, Virginia,1 Public Health, Ancona, Italy,2 Instituto Salud Carlos III, Majadahonda, Spain,3 University of Texas Health Science Center, San Antonio, Texas,4 University of Iowa College of Medicine, Iowa City, Iowa,5 Medical Center Nijmegen, Nijmegen, The Netherlands6
2 shared publicationsJ. L. Rodriguez-Tudela
VCU Medical Center, Richmond, Virginia,1 Public Health, Ancona, Italy,2 Instituto Salud Carlos III, Majadahonda, Spain,3 University of Texas Health Science Center, San Antonio, Texas,4 University of Iowa College of Medicine, Iowa City, Iowa,5 Medical Center Nijmegen, Nijmegen, The Netherlands6
2 shared publicationsM. Cuenca-Estrella
VCU Medical Center, Richmond, Virginia,1 Public Health, Ancona, Italy,2 Instituto Salud Carlos III, Majadahonda, Spain,3 University of Texas Health Science Center, San Antonio, Texas,4 University of Iowa College of Medicine, Iowa City, Iowa,5 Medical Center Nijmegen, Nijmegen, The Netherlands6
2 shared publications
Latest Publications
- Open Access
- 1 October 2005
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 43 (10) , 5243-5246
Quality Control and Reference Guidelines for CLSI Broth Microdilution Susceptibility Method (M38-A Document) for Amphotericin B, Itraconazole, Posaconazole, and Voriconazole
Although standard conditions are available for testing the susceptibilities of filamentous fungi to antifungal agents by the Clinical and Laboratory Standards Institute (CLSI; formerly National Committee for Clinical Laboratory Standards) broth microdilution assay, quality control (QC) MIC limits have not been established for any mold-agent combination. This multicenter (eight-center) study documented the reproducibility of tests for one isolate of Paecilomyces variotii ATCC MYA-3630 and 11 other mold isolates (three isolates of Aspergillus fumigatus ; two isolates of A. terreus ; one isolate each of A. flavus , A. nidulans , Fusarium moniliforme , and F. solani ; and two isolates of Scedosporium apiospermum ) by the CLSI reference broth microdilution method (M38-A document). Control limits (amphotericin B, 1 to 4 μg/ml; itraconazole, 0.06 to 0.5 μg/ml; posaconazole, 0.03 to 0.25 μg/ml; voriconazole, 0.015 to 0.12 μg/ml) for the selected QC P. variotii ATCC MYA-3630 were established by the analysis of replicate MIC results. Reference isolates and corresponding MIC ranges were also established for 6 of the 12 molds evaluated. MIC limits were not proposed for the other five molds tested due to low testing reproducibility for these isolates.
- 1 October 2005
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 43 (10) , 5243-5246
Open AccessQuality Control and Reference Guidelines for CLSI Broth Microdilution Susceptibility Method (M38-A Document) for Amphotericin B, Itraconazole, Posaconazole, and Voriconazole
Although standard conditions are available for testing the susceptibilities of filamentous fungi to antifungal agents by the Clinical and Laboratory Standards Institute (CLSI; formerly National Committee for Clinical Laboratory Standards) broth microdilution assay, quality control (QC) MIC limits have not been established for any mold-agent combination. This multicenter (eight-center) study documented the reproducibility of tests for one isolate of Paecilomyces variotii ATCC MYA-3630 and 11 other mold isolates (three isolates of Aspergillus fumigatus ; two isolates of A. terreus ; one isolate each of A. flavus , A. nidulans , Fusarium moniliforme , and F. solani ; and two isolates of Scedosporium apiospermum ) by the CLSI reference broth microdilution method (M38-A document). Control limits (amphotericin B, 1 to 4 μg/ml; itraconazole, 0.06 to 0.5 μg/ml; posaconazole, 0.03 to 0.25 μg/ml; voriconazole, 0.015 to 0.12 μg/ml) for the selected QC P. variotii ATCC MYA-3630 were established by the analysis of replicate MIC results. Reference isolates and corresponding MIC ranges were also established for 6 of the 12 molds evaluated. MIC limits were not proposed for the other five molds tested due to low testing reproducibility for these isolates.
- 1 September 2005
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 43 (9) , 4535-4540
Comparison of Visual 24-Hour and Spectrophotometric 48-Hour MICs to CLSI Reference Microdilution MICs of Fluconazole, Itraconazole, Posaconazole, and Voriconazole for Candida spp.: a Collaborative Study
A multicenter (six-center) study evaluated the performance (interlaboratory reproducibility, compatibility with reference methods, and categorical agreement) of 24-h visual and 48-h spectrophotometric MICs. MICs of fluconazole, itraconazole, voriconazole, and posaconazole were compared to reference 48-h microdilution broth visual MICs (CLSI [formerly NCCLS] M27-A2 document) for 71 isolates of Candida spp. that included 10 fluconazole-resistant strains. Twenty readings (5%) were reported as showing no growth at 24 h, mostly for Candida dubliniensis and from a single center. The overall interlaboratory agreement of 24-h visual readings and 48-h spectrophotometric MICs, as well their compatibility with reference values, were excellent with the four triazoles for most of the species (93 to 99%, within 3 dilutions). The categorical agreement between the investigational reading conditions and reference values was good with fluconazole and voriconazole (93 to 97%) but lower with itraconazole (86 to 88%), due primarily to minor errors. There were only 0 to 3% very major errors with these three triazoles; the number of substantial errors (more than three dilutions) was also low (<2%) with posaconazole. These data suggest that the performance of both investigational MIC readings gives results similar to those of reference MICs. Since spectrophotometric MICs are more objective and the 24-h time period would shorten the MIC determination of azoles, the description of either of these two reading conditions in the M27-A2 document should be considered by the CLSI subcommittee in addition to or instead of the longer, less practical, and more subjective 48-h visual MIC reading.
- 1 September 2005
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 43 (9) , 4535-4540
Comparison of Visual 24-Hour and Spectrophotometric 48-Hour MICs to CLSI Reference Microdilution MICs of Fluconazole, Itraconazole, Posaconazole, and Voriconazole for Candida spp.: a Collaborative Study
A multicenter (six-center) study evaluated the performance (interlaboratory reproducibility, compatibility with reference methods, and categorical agreement) of 24-h visual and 48-h spectrophotometric MICs. MICs of fluconazole, itraconazole, voriconazole, and posaconazole were compared to reference 48-h microdilution broth visual MICs (CLSI [formerly NCCLS] M27-A2 document) for 71 isolates of Candida spp. that included 10 fluconazole-resistant strains. Twenty readings (5%) were reported as showing no growth at 24 h, mostly for Candida dubliniensis and from a single center. The overall interlaboratory agreement of 24-h visual readings and 48-h spectrophotometric MICs, as well their compatibility with reference values, were excellent with the four triazoles for most of the species (93 to 99%, within 3 dilutions). The categorical agreement between the investigational reading conditions and reference values was good with fluconazole and voriconazole (93 to 97%) but lower with itraconazole (86 to 88%), due primarily to minor errors. There were only 0 to 3% very major errors with these three triazoles; the number of substantial errors (more than three dilutions) was also low (<2%) with posaconazole. These data suggest that the performance of both investigational MIC readings gives results similar to those of reference MICs. Since spectrophotometric MICs are more objective and the 24-h time period would shorten the MIC determination of azoles, the description of either of these two reading conditions in the M27-A2 document should be considered by the CLSI subcommittee in addition to or instead of the longer, less practical, and more subjective 48-h visual MIC reading.
- Open Access
- 1 August 2005
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 43 (8) , 3884-3889
International and Multicenter Comparison of EUCAST and CLSI M27-A2 Broth Microdilution Methods for Testing Susceptibilities of Candida spp. to Fluconazole, Itraconazole, Posaconazole, and Voriconazole
The aim of this study was to compare MICs of fluconazole, itraconazole, posaconazole, and voriconazole obtained by the European Committee on Antibiotic Susceptibility Testing (EUCAST) and CLSI (formerly NCCLS) methods in each of six centers for 15 Candida albicans (5 fluconazole-resistant and 4 susceptible-dose-dependent [S-DD] isolates), 10 C. dubliniensis , 7 C. glabrata (2 fluconazole-resistant isolates), 5 C. guilliermondii (2 fluconazole-resistant isolates), 10 C. krusei , 9 C. lusitaniae , 10 C. parapsilosis , and 5 C. tropicalis (1 fluconazole-resistant isolate) isolates. CLSI MICs were obtained visually at 24 and 48 h and spectrophotometric EUCAST MICs at 24 h. The agreement (within a 3-dilution range) between the methods was species, drug, and incubation time dependent and due to lower EUCAST than CLSI MICs: overall, 94 to 95% with fluconazole and voriconazole and 90 to 91% with posaconazole and itraconazole when EUCAST MICs were compared against 24-h CLSI results. The agreement was lower (85 to 94%) against 48-h CLSI endpoints. The overall interlaboratory reproducibility by each method was ≥92%. When the comparison was based on CLSI breakpoint categorization, the agreement was 68 to 76% for three of the four species that included fluconazole-resistant and S-DD isolates; 9% very major discrepancies (≤8 μg/ml versus ≥64 μg/ml) were observed among fluconazole-resistant isolates and 50% with voriconazole (≤1 μg/ml versus ≥4 μg/ml). Similar results were observed with itraconazole for seven of the eight species evaluated (28 to 77% categorical agreement). Posaconazole EUCAST MICs were also substantially lower than CLSI MIC modes (0.008 to 1 μg/ml versus 1 to ≥8 μg/ml) for some of these isolates. Therefore, the CLSI breakpoints should not be used to interpret EUCAST MIC data.
- 1 August 2005
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 43 (8) , 3884-3889
Open AccessInternational and Multicenter Comparison of EUCAST and CLSI M27-A2 Broth Microdilution Methods for Testing Susceptibilities of Candida spp. to Fluconazole, Itraconazole, Posaconazole, and Voriconazole
The aim of this study was to compare MICs of fluconazole, itraconazole, posaconazole, and voriconazole obtained by the European Committee on Antibiotic Susceptibility Testing (EUCAST) and CLSI (formerly NCCLS) methods in each of six centers for 15 Candida albicans (5 fluconazole-resistant and 4 susceptible-dose-dependent [S-DD] isolates), 10 C. dubliniensis , 7 C. glabrata (2 fluconazole-resistant isolates), 5 C. guilliermondii (2 fluconazole-resistant isolates), 10 C. krusei , 9 C. lusitaniae , 10 C. parapsilosis , and 5 C. tropicalis (1 fluconazole-resistant isolate) isolates. CLSI MICs were obtained visually at 24 and 48 h and spectrophotometric EUCAST MICs at 24 h. The agreement (within a 3-dilution range) between the methods was species, drug, and incubation time dependent and due to lower EUCAST than CLSI MICs: overall, 94 to 95% with fluconazole and voriconazole and 90 to 91% with posaconazole and itraconazole when EUCAST MICs were compared against 24-h CLSI results. The agreement was lower (85 to 94%) against 48-h CLSI endpoints. The overall interlaboratory reproducibility by each method was ≥92%. When the comparison was based on CLSI breakpoint categorization, the agreement was 68 to 76% for three of the four species that included fluconazole-resistant and S-DD isolates; 9% very major discrepancies (≤8 μg/ml versus ≥64 μg/ml) were observed among fluconazole-resistant isolates and 50% with voriconazole (≤1 μg/ml versus ≥4 μg/ml). Similar results were observed with itraconazole for seven of the eight species evaluated (28 to 77% categorical agreement). Posaconazole EUCAST MICs were also substantially lower than CLSI MIC modes (0.008 to 1 μg/ml versus 1 to ≥8 μg/ml) for some of these isolates. Therefore, the CLSI breakpoints should not be used to interpret EUCAST MIC data.
- Open Access
- 1 March 2004
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 42 (3) , 1257-1259
Long-Term Preservation of Fungal Isolates in Commercially Prepared Cryogenic Microbank Vials
Since 1994, 6,198 yeasts and 391 molds belonging to 25 and 37 species, respectively, were stored in Microbank cryogenic vials at ≥−130°C in liquid nitrogen and at −70°C in a freezer. All of the isolates, with the exception of 45 yeasts and 15 dermatophytes, were recovered from both storage temperatures. Good reproducibility was demonstrated for amphotericin B, fluconazole, and voriconazole MICs determined for random isolates.
- 1 March 2004
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 42 (3) , 1257-1259
Open AccessLong-Term Preservation of Fungal Isolates in Commercially Prepared Cryogenic Microbank Vials
Since 1994, 6,198 yeasts and 391 molds belonging to 25 and 37 species, respectively, were stored in Microbank cryogenic vials at ≥−130°C in liquid nitrogen and at −70°C in a freezer. All of the isolates, with the exception of 45 yeasts and 15 dermatophytes, were recovered from both storage temperatures. Good reproducibility was demonstrated for amphotericin B, fluconazole, and voriconazole MICs determined for random isolates.
- 1 December 2003
- Published by Wolters Kluwer Health in Current Opinion in Infectious Diseases
- Vol. 16 (6) , 527-532
Utility of mould susceptibility testing
As new antifungal agents were introduced for the treatment of fungal infections, reliable methods were developed or adapted for the in-vitro susceptibility testing of yeasts and moulds (filamentous fungi). This paper reviews the available methods for antifungal susceptibility testing of moulds as well as the scant data that have been published since 2002 regarding the clinical implications of in-vitro testing. Caspofungin and voriconazole have been recently licensed for treatment of certain mould infections that are usually refractory to treatment with established agents. The introduction of new agents and the frequent reports of mould resistance have underscored the role of the laboratory in patient management and initiated the study of mechanisms of resistance in moulds. In 2002, the US National Committee for Clinical Laboratory Standards M38-P document moved to the approved level of development (M38-A document). Although combination therapy and synergistic studies with the new agents have been documented, very little information is available on in-vitro/in-vivo correlations for moulds. The ultimate goal of in-vitro testing is the prediction of the clinical outcome of therapy. The use of National Committee for Clinical Laboratory Standards procedures has led to increased interlaboratory agreement of minimum inhibitory concentrations. Reproducibility of minimum inhibitory concentrations for yeasts has facilitated the establishment of interpretive breakpoints for fluconazole and itraconazole versus Candida spp., but breakpoints are not available for any antifungal against mould species. Although some insights have been documented regarding the potential utility of in-vitro testing for moulds, further documentation of in-vitro versus in-vivo data is needed.
- 1 December 2003
- Published by Wolters Kluwer Health in Current Opinion in Infectious Diseases
- Vol. 16 (6) , 527-532
Utility of mould susceptibility testing
As new antifungal agents were introduced for the treatment of fungal infections, reliable methods were developed or adapted for the in-vitro susceptibility testing of yeasts and moulds (filamentous fungi). This paper reviews the available methods for antifungal susceptibility testing of moulds as well as the scant data that have been published since 2002 regarding the clinical implications of in-vitro testing. Caspofungin and voriconazole have been recently licensed for treatment of certain mould infections that are usually refractory to treatment with established agents. The introduction of new agents and the frequent reports of mould resistance have underscored the role of the laboratory in patient management and initiated the study of mechanisms of resistance in moulds. In 2002, the US National Committee for Clinical Laboratory Standards M38-P document moved to the approved level of development (M38-A document). Although combination therapy and synergistic studies with the new agents have been documented, very little information is available on in-vitro/in-vivo correlations for moulds. The ultimate goal of in-vitro testing is the prediction of the clinical outcome of therapy. The use of National Committee for Clinical Laboratory Standards procedures has led to increased interlaboratory agreement of minimum inhibitory concentrations. Reproducibility of minimum inhibitory concentrations for yeasts has facilitated the establishment of interpretive breakpoints for fluconazole and itraconazole versus Candida spp., but breakpoints are not available for any antifungal against mould species. Although some insights have been documented regarding the potential utility of in-vitro testing for moulds, further documentation of in-vitro versus in-vivo data is needed.
- Open Access
- 1 January 2003
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 41 (1) , 403-409
Evaluation of Broth Microdilution Testing Parameters and Agar Diffusion Etest Procedure for Testing Susceptibilities of Aspergillus spp. to Caspofungin Acetate (MK-0991)
The NCCLS M38-A document does not describe guidelines for testing caspofungin acetate (MK-0991) and other echinocandins against molds. This study evaluated the susceptibilities of 200 isolates of Aspergillus fumigatus , A. flavus , A. nidulans , A. niger , and A. terreus to caspofungin (MICs and minimum effective concentrations [MECs]) by using standard RPMI 1640 (RPMI) and antibiotic medium 3 (M3), two inoculum sizes (10 3 and 10 4 CFU/ml), and two MIC determination criteria (complete [MICs-0] and prominent growth inhibition [MICs-2]) at 24 and 48 h. Etest MICs were also determined. In general, caspofungin MIC-2 and MEC pairs were comparable with both media and inocula (geometric mean ranges of MECs and MICs, respectively, with larger inoculum: 0.12 to 0.64 μg/ml and 0.12 to 0.44 μg/ml with RPMI versus 0.04 to 0.51 μg/ml and 0.03 to 0.21 μg/ml with M3); however, MEC results were less influenced by testing conditions than MICs, especially with the larger inoculum. Overall, the agreement between caspofungin Etest MICs and broth dilution values was higher with MECs obtained with M3 (>90%) and the large inoculum than under the other testing conditions. Because RPMI is a more stable and chemically defined medium than M3, the determination at 24 h of the easier visual MECs with RPMI and the inoculum recommended in the M38-A document appears to be a suitable procedure at present for in vitro testing of caspofungin against Aspergillus spp. Future in vitro correlations with in vivo outcome of both microdilution and Etest procedures may detect more-relevant testing conditions.
- 1 January 2003
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 41 (1) , 403-409
Open AccessEvaluation of Broth Microdilution Testing Parameters and Agar Diffusion Etest Procedure for Testing Susceptibilities of Aspergillus spp. to Caspofungin Acetate (MK-0991)
The NCCLS M38-A document does not describe guidelines for testing caspofungin acetate (MK-0991) and other echinocandins against molds. This study evaluated the susceptibilities of 200 isolates of Aspergillus fumigatus , A. flavus , A. nidulans , A. niger , and A. terreus to caspofungin (MICs and minimum effective concentrations [MECs]) by using standard RPMI 1640 (RPMI) and antibiotic medium 3 (M3), two inoculum sizes (10 3 and 10 4 CFU/ml), and two MIC determination criteria (complete [MICs-0] and prominent growth inhibition [MICs-2]) at 24 and 48 h. Etest MICs were also determined. In general, caspofungin MIC-2 and MEC pairs were comparable with both media and inocula (geometric mean ranges of MECs and MICs, respectively, with larger inoculum: 0.12 to 0.64 μg/ml and 0.12 to 0.44 μg/ml with RPMI versus 0.04 to 0.51 μg/ml and 0.03 to 0.21 μg/ml with M3); however, MEC results were less influenced by testing conditions than MICs, especially with the larger inoculum. Overall, the agreement between caspofungin Etest MICs and broth dilution values was higher with MECs obtained with M3 (>90%) and the large inoculum than under the other testing conditions. Because RPMI is a more stable and chemically defined medium than M3, the determination at 24 h of the easier visual MECs with RPMI and the inoculum recommended in the M38-A document appears to be a suitable procedure at present for in vitro testing of caspofungin against Aspergillus spp. Future in vitro correlations with in vivo outcome of both microdilution and Etest procedures may detect more-relevant testing conditions.
- Open Access
- 1 October 2002
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 40 (10) , 3776-3781
Optimal Testing Conditions for Determining MICs and Minimum Fungicidal Concentrations of New and Established Antifungal Agents for Uncommon Molds: NCCLS Collaborative Study
This collaborative three-center study evaluated NCCLS M38-A document testing conditions and other testing conditions for the antifungal susceptibility testing of 35 isolates of Aspergillus nidulans , A. terreus , Bipolaris hawaiiensis , B. spicifera , Cladophialophora bantiana , Dactylaria constricta , Fusarium solani , Paecilomyces lilacinus , Scedosporium prolificans , Trichoderma longibrachiatum , and Wangiella dermatitidis for itraconazole, three new triazoles (voriconazole, posaconazole, and ravuconazole), and amphotericin B. MICs and minimum fungicidal concentrations (MFCs) were determined in each center by using four media (standard RPMI-1640 [RPMI], RPMI with 2% dextrose [RPMI-2%], antibiotic medium 3 [M3], and M3 with 2% dextrose [M3-2%]) and two criteria of MIC determination (complete growth inhibition [MICs-0] and prominent growth inhibition [MICs-2]) at 24, 48 and 72 h. MFCs were defined as the lowest drug concentrations that yielded <3 colonies (approximately 99 to 99.5% killing activity). The reproducibility (within three wells) was higher among MICs-0 (93 to 99%) with either RPMI or M3 media than among all MICs-2 (86 to 95%) for the five agents at 48 to 72 h. The agreement for MFCs was lower (86 to 94%). Based on interlaboratory agreement, the optimal testing conditions were RPMI broth, 48 to 72 h of incubation and 100% growth inhibition (MIC-0); MFCs can be obtained after MIC determination with the above optimal testing parameters. These results warrant consideration for inclusion in the future version of the NCCLS M38 document. However, the role of these in vitro values as predictors of clinical outcome remains to be established in clinical trials.
- 1 October 2002
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 40 (10) , 3776-3781
Open AccessOptimal Testing Conditions for Determining MICs and Minimum Fungicidal Concentrations of New and Established Antifungal Agents for Uncommon Molds: NCCLS Collaborative Study
This collaborative three-center study evaluated NCCLS M38-A document testing conditions and other testing conditions for the antifungal susceptibility testing of 35 isolates of Aspergillus nidulans , A. terreus , Bipolaris hawaiiensis , B. spicifera , Cladophialophora bantiana , Dactylaria constricta , Fusarium solani , Paecilomyces lilacinus , Scedosporium prolificans , Trichoderma longibrachiatum , and Wangiella dermatitidis for itraconazole, three new triazoles (voriconazole, posaconazole, and ravuconazole), and amphotericin B. MICs and minimum fungicidal concentrations (MFCs) were determined in each center by using four media (standard RPMI-1640 [RPMI], RPMI with 2% dextrose [RPMI-2%], antibiotic medium 3 [M3], and M3 with 2% dextrose [M3-2%]) and two criteria of MIC determination (complete growth inhibition [MICs-0] and prominent growth inhibition [MICs-2]) at 24, 48 and 72 h. MFCs were defined as the lowest drug concentrations that yielded <3 colonies (approximately 99 to 99.5% killing activity). The reproducibility (within three wells) was higher among MICs-0 (93 to 99%) with either RPMI or M3 media than among all MICs-2 (86 to 95%) for the five agents at 48 to 72 h. The agreement for MFCs was lower (86 to 94%). Based on interlaboratory agreement, the optimal testing conditions were RPMI broth, 48 to 72 h of incubation and 100% growth inhibition (MIC-0); MFCs can be obtained after MIC determination with the above optimal testing parameters. These results warrant consideration for inclusion in the future version of the NCCLS M38 document. However, the role of these in vitro values as predictors of clinical outcome remains to be established in clinical trials.
- Open Access
- 1 September 2002
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 40 (9) , 3204-3208
Testing Conditions for Determination of Minimum Fungicidal Concentrations of New and Established Antifungal Agents for Aspergillus spp.: NCCLS Collaborative Study
Standard conditions are not available for evaluating the minimum fungicidal concentrations (MFCs) of antifungal agents. This multicenter collaborative study investigated the reproducibility in three laboratories of itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B MFCs for 15 selected isolates of Aspergillus spp. After MIC determinations for the 15 isolates in each center by the NCCLS M38-A broth microdilution method with four media, standard RPMI 1640 (RPMI), RPMI with 2% dextrose, antibiotic medium 3 (M3), and M3 with 2% dextrose, MFCs were determined for each isolate-medium-drug combination. MFCs were defined as the lowest drug dilutions that yielded Aspergillus spp. and warrant consideration for introduction into future versions of the M38 document. The role of the MFC under these standardized testing conditions as a predictor of clinical outcome needs to be established in clinical trials.
- 1 September 2002
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 40 (9) , 3204-3208
Open AccessTesting Conditions for Determination of Minimum Fungicidal Concentrations of New and Established Antifungal Agents for Aspergillus spp.: NCCLS Collaborative Study
Standard conditions are not available for evaluating the minimum fungicidal concentrations (MFCs) of antifungal agents. This multicenter collaborative study investigated the reproducibility in three laboratories of itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B MFCs for 15 selected isolates of Aspergillus spp. After MIC determinations for the 15 isolates in each center by the NCCLS M38-A broth microdilution method with four media, standard RPMI 1640 (RPMI), RPMI with 2% dextrose, antibiotic medium 3 (M3), and M3 with 2% dextrose, MFCs were determined for each isolate-medium-drug combination. MFCs were defined as the lowest drug dilutions that yielded Aspergillus spp. and warrant consideration for introduction into future versions of the M38 document. The role of the MFC under these standardized testing conditions as a predictor of clinical outcome needs to be established in clinical trials.
- Open Access
- 1 June 2002
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 40 (6) , 2101-2107
E-Test Method for Testing Susceptibilities of Aspergillus spp. to the New Triazoles Voriconazole and Posaconazole and to Established Antifungal Agents: Comparison with NCCLS Broth Microdilution Method
NCCLS document M38-P describes standard parameters for testing the fungistatic activities (MICs) of established agents against filamentous fungi (molds). This study evaluated the in vitro susceptibilities of 15 Aspergillus flavus isolates, 62 A. fumigatus isolates, and 10 isolates each of A. niger , A. nidulans , and A. terreus to voriconazole, posaconazole, itraconazole, and amphotericin B by the E-test and NCCLS M38-P microdilution methods. The agreement (within 3 dilutions) between methods for voriconazole was independent of the E-test incubation time (93.3 to 100% for four of five species at both incubation times). In contrast, with amphotericin B, itraconazole, and posaconazole, E-test results were more dependent on the incubation time for certain species. For A. fumigatus, posaconazole E-test MICs had better concordance with reference values after 48 h (95.2%) than after 24 h (90%), while the highest agreement for itraconazole MICs was after 24 h (90.3 versus 74.2%) of incubation. Better agreement between the methods was also obtained with 24-h E-test amphotericin B MICs for A. flavus (73.3 versus 26.7%) and A. fumigatus (96.7 versus 64.5%). E-test MICs of the four agents had the lowest percentages of agreement with reference values for A. nidulans (60 to 80%). For isolates for which high MICs were obtained for the four agents by the reference method, high MICs were also obtained by E-test at both 24 and 48 h. The utility of in vitro results of either the E-test or the NCCLS broth microdilution (M38-P) method for Aspergillus spp. needs to be established in clinical trials.
- 1 June 2002
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 40 (6) , 2101-2107
Open AccessE-Test Method for Testing Susceptibilities of Aspergillus spp. to the New Triazoles Voriconazole and Posaconazole and to Established Antifungal Agents: Comparison with NCCLS Broth Microdilution Method
NCCLS document M38-P describes standard parameters for testing the fungistatic activities (MICs) of established agents against filamentous fungi (molds). This study evaluated the in vitro susceptibilities of 15 Aspergillus flavus isolates, 62 A. fumigatus isolates, and 10 isolates each of A. niger , A. nidulans , and A. terreus to voriconazole, posaconazole, itraconazole, and amphotericin B by the E-test and NCCLS M38-P microdilution methods. The agreement (within 3 dilutions) between methods for voriconazole was independent of the E-test incubation time (93.3 to 100% for four of five species at both incubation times). In contrast, with amphotericin B, itraconazole, and posaconazole, E-test results were more dependent on the incubation time for certain species. For A. fumigatus, posaconazole E-test MICs had better concordance with reference values after 48 h (95.2%) than after 24 h (90%), while the highest agreement for itraconazole MICs was after 24 h (90.3 versus 74.2%) of incubation. Better agreement between the methods was also obtained with 24-h E-test amphotericin B MICs for A. flavus (73.3 versus 26.7%) and A. fumigatus (96.7 versus 64.5%). E-test MICs of the four agents had the lowest percentages of agreement with reference values for A. nidulans (60 to 80%). For isolates for which high MICs were obtained for the four agents by the reference method, high MICs were also obtained by E-test at both 24 and 48 h. The utility of in vitro results of either the E-test or the NCCLS broth microdilution (M38-P) method for Aspergillus spp. needs to be established in clinical trials.
- 1 June 2001
- Published by Springer Nature in Mycopathologia
- Vol. 150 (3) , 101-115
In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: Review of the literature
Voriconazole (Vfend™) is a new triazole that currently is undergoing phase III clinical trials. This review summarizes the published data obtained by NCCLS methods on the in vitro antifungal activity...
- 1 June 2001
- Published by Springer Nature in Mycopathologia
- Vol. 150 (3) , 101-115
In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: Review of the literature
Voriconazole (Vfend™) is a new triazole that currently is undergoing phase III clinical trials. This review summarizes the published data obtained by NCCLS methods on the in vitro antifungal activity...